Phase 1 N=35 Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Inflammation · Cataract
Primary: Visual Acuity — 20.3; 20.2 units on a scale — p=.374
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=406 An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response. — 224; 126; 350; 221 Participants
Phase 4 N=936 Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
Wet Age Related Macular Degeneration
Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants
N/A N=50 Cefaly® Device in the Treatment of Patients With Fibromyalgia.
Fibromyalgia
Primary: Change in Pain Intensity (Fibromyalgia Impact Questionnaire-revised (FIQR) Pain Score) Between Baseline and 12-week Timepoint — -1.33 score on a scale
N/A N=569 Effective Screening for Pain Study
Pain · Pain Management
Primary: Arm 1 (NRS Now), to Arm 2 (PEG), to Arm 3 (Defense Veterans Pain Rating Scale (e.g.,DVPRS) Differences Baseline Overall Pain Compared With Gold Standard Chronic Pain…
N/A N=449 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
N/A N=600 A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
Infertility
Primary: Number of Participants With Adverse Event (AE) and Adverse Drug Reaction (ADR) — 16; 13 Participants
N/A N=112 A Pilot Study to Estimate the Impact of a Screening and Referral Service on Contraceptive Use
Contraception Behavior
Primary: Number of Participants Who Report Starting Any Modern Method of Contraception Since the Start of the Study — 17; 9 Participants
Phase 4 N=46 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
N/A N=80 Non-pharmacological Resources in Assisting Labor
Labour Pain
Primary: Pain Relief — 79.5; 73.8; 71.0; 51.7 millimeters
Phase 1 N=10 Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI
Spinal Cord Injury
Primary: Efficacy-Sensivity Improvement Using the ASIA Score — 188.2; 202.2; 218.4; 228.9 units on a scale
N/A N=39 Change of Fructose to Fat in South Asians
Elevated Triglycerides · Diabetes · Cardiovascular Disease
Primary: Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate — 1.24; 1.85 fold change — p=0.05
N/A N=48 Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults
Mild Cognitive Impairment
Primary: Cognition — .90; .86; .92; .92 units on a scale
Phase 4 N=293 Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
Iron Deficiency Anemia Treatment · Chronic Kidney Disease(CKD)
Primary: Hemoglobin Changes — 0.5; 0.4; 0.6; 0.3 g/dL — p=<0.05
Phase 1 N=49 A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
Infectious Disease
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN® — 73.5; 45.0; 115; 52.3 µM*hr